To answer this effectively, we must narrow the scope to a clinical scenario where sequential targeted therapies are the standard of care. The clearest and most clinically developed example of this evolutionary biology in action is **EGFR-mutant Non-Small Cell Lung Cancer (NSCLC)**.

This disease model offers the perfect illustration of how resistance mutations evolve specifically based on the drug used in the previous line.

Here is an analysis of how resistance patterns vary by line of therapy in **EGFR-mutant NSCLC**, followed by general principles applicable to other cancers.

---

### Case Study: EGFR-Mutant NSCLC
**Scenario:** A patient presents with metastatic adenocarcinoma of the lung harboring an *EGFR* Exon 19 deletion (sensitizing mutation).

#### 1. First-Line Therapy (The "Old" Standard Sequence)
*Context: Historically, patients started with 1st or 2nd generation Tyrosine Kinase Inhibitors (TKIs) like Erlotinib, Gefitinib, or Afatinib.*

*   **Mechanism of Action:** These drugs bind reversibly (1st gen) or irreversibly (2nd gen) to the ATP-binding pocket of the EGFR protein, shutting down signaling.
*   **Resistance Pattern (Post-1st Line):** Under the selective pressure of these drugs, the tumor evolves a specific mechanism to block the drug while keeping the receptor active.
*   **The Dominant Mutation:** **T790M (The "Gatekeeper").**
    *   In **50â€“60%** of patients progressing on 1st/2nd gen TKIs, the tumor develops a substitution at position 790 (Threonine to Methionine).
    *   **Why?** This bulky methionine residue physically blocks the 1st generation drug from binding but still allows ATP to bind, restoring tumor growth.
    *   **Clinical Implication:** The presence of T790M dictated the specific use of the 2nd-line drug.

#### 2. Second-Line Therapy
*Context: The patient has developed the T790M mutation. They are now treated with Osimertinib (a 3rd generation TKI designed specifically to bind despite the T790M mutation).*

*   **Mechanism of Action:** Osimertinib forms a covalent bond with a specific cysteine residue (C797) within the ATP binding pocket.
*   **Resistance Pattern (Post-2nd Line):** The tumor is now under pressure to prevent this covalent bond.
*   **The Dominant Mutation:** **C797S.**
    *   The tumor mutates the Cysteine at position 797 to a Serine.
    *   **Why?** Without the cysteine, Osimertinib cannot form the necessary covalent bond to anchor itself.
    *   **Allelic Context:** It matters if C797S occurs on the *same* allele (cis) as T790M or a *different* allele (trans). If it is in *trans*, a combination of 1st and 3rd gen drugs might theoretically work (though rarely done); if in *cis*, the tumor is resistant to all current EGFR TKIs.

#### 3. Current Standard (Osimertinib as 1st Line)
*Context: Today, Osimertinib is usually given as 1st line. This changes the resistance landscape entirely.*

*   **Resistance Pattern:** Because the tumor was never exposed to 1st-gen drugs, there was no pressure to develop T790M. Therefore, T790M is rarely seen after 1st-line Osimertinib.
*   **The Pattern:** Resistance is much more heterogeneous (diverse) compared to the sequential approach.
    *   **MET Amplification:** The tumor bypasses EGFR entirely and uses the MET receptor to drive growth (15-20%).
    *   **Histologic Transformation:** The cancer changes its identity from Adenocarcinoma to Small Cell Lung Cancer (SCLC), losing EGFR dependence (~5-10%).
    *   **C797S:** Still occurs (7%), but less frequently than in the 2nd-line setting.
    *   **Gene Fusions:** ALK or RET fusions may arise.

---

### Secondary Example: HR+/HER2- Breast Cancer
*Resistance patterns here are defined by the emergence of mutations that are rare at diagnosis but common after therapy.*

*   **1st Line (Aromatase Inhibitor + CDK4/6 Inhibitor):**
    *   The tumor is deprived of estrogen.
    *   **Resistance Pattern:** The tumor mutates the Estrogen Receptor (ER) so it stays "on" even without estrogen.
    *   **Specific Mutation:** **ESR1 mutations** (e.g., Y537S). These are almost non-existent in primary breast cancer but are found in up to 40% of metastatic patients who have progressed on Aromatase Inhibitors.
*   **2nd Line (Fulvestrant or Novel SERDs):**
    *   If an *ESR1* mutation is detected via liquid biopsy (ctDNA) after 1st line, doctors may switch to Fulvestrant (which degrades the receptor) rather than another Aromatase Inhibitor (which would be useless since the receptor no longer needs estrogen).

---

### General Principles: How Patterns Change by Line

If we zoom out from specific diseases, three general rules govern resistance evolution across lines of therapy:

#### 1. From "On-Target" to "Off-Target"
*   **Early Lines (1st/2nd):** Resistance is often **"On-Target."** The tumor mutates the specific drug-binding pocket (e.g., T790M in lung, ABL kinase mutations in CML). The driver is the same, but the lock has changed.
*   **Later Lines (3rd+):** Resistance becomes **"Off-Target" (Bypass Tracks).** The tumor realizes the primary pathway (e.g., EGFR) is completely blocked, so it activates a parallel pathway (e.g., MET, HER2, or RAS) to survive.

#### 2. Increasing Heterogeneity (Polyclonality)
*   **1st Line Failure:** Usually driven by a single dominant clone (e.g., almost all cells have T790M).
*   **3rd Line Failure:** The tumor is a "mosaic." One metastatic site might be driven by a MET amplification, while another site in the liver is driven by a KRAS mutation. This makes 3rd-line targeted therapy very difficult, often necessitating broad-spectrum chemotherapy or Antibody-Drug Conjugates (ADCs).

#### 3. Phenotypic Plasticity (Identity Change)
*   In late-line settings (prostate and lung cancer specifically), tumors often undergo **lineage plasticity**.
*   **Example:** Neuroendocrine differentiation. An Adenocarcinoma transforms into Small Cell Carcinoma. It stops expressing the target (EGFR or Androgen Receptor) entirely, rendering targeted drugs useless and requiring platinum-based chemotherapy.

### Summary Table (EGFR NSCLC Model)

| Line of Therapy | Drug Class | Primary Resistance Mechanism | Type of Resistance |
| :--- | :--- | :--- | :--- |
| **1st Line** | 1st/2nd Gen TKI (Erlotinib) | **T790M** (Gatekeeper mutation) | On-Target (Binding site alteration) |
| **2nd Line** | 3rd Gen TKI (Osimertinib) | **C797S** (Covalent bond site loss) | On-Target (Binding site alteration) |
| **Late Line** | Any TKI | **MET Amp, HER2 Amp, Small Cell Transformation** | Off-Target (Bypass track / Phenotype change) |

**Clinical Takeaway:** This variance dictates the necessity of **re-biopsy (tissue or liquid/ctDNA)** at every progression. You cannot treat 2nd or 3rd line progression based on the mutation profile obtained at diagnosis.